Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,460	Closed	-$223K	–	80
2021 Q4	$223K	Hold	1,460	–	–	0.05%	82
2021 Q3	$236K	Hold	1,460	–	–	0.05%	79
2021 Q2	$239K	Hold	1,460	–	–	0.05%	73
2021 Q1	$220K	Hold	1,460	–	–	0.05%	71
2020 Q4	$221K	Buy	+1,460	New	+$209K	0.06%	69
2020 Q2	–	Sell	-1,940	Closed	-$209K	–	70
2020 Q1	$209K	Hold	1,940	–	–	0.08%	68
2019 Q4	$234K	Buy	+1,940	New	+$216K	0.06%	76
2019 Q3	–	Sell	-1,940	Closed	-$212K	–	84
2019 Q2	$212K	Buy	1,940 +90	+5%	+$9.57K	0.06%	74
2019 Q1	$207K	Buy	+1,850	New	+$203K	0.06%	80
2018 Q4	–	Sell	-1,995	Closed	-$243K	–	79
2018 Q3	$243K	Hold	1,995	–	–	0.06%	75
2018 Q2	$219K	Hold	1,995	–	–	0.06%	76
2018 Q1	$213K	Sell	1,995 -125	-6%	-$13.9K	0.06%	88
2017 Q4	$226K	Buy	2,120 +5	+0.2%	+$534	0.06%	88
2017 Q3	$235K	Sell	2,115 -195	-8%	-$20.8K	0.07%	80
2017 Q2	$239K	Buy	2,310 +45	+2%	+$4.43K	0.07%	81
2017 Q1	$221K	Buy	+2,265	New	+$217K	0.07%	88

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Management's IBB Position: Q1 2022 in Review

Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 1,460 shares — an estimated $223K sold.

Capital Management first reported a position in IBB in Q1 2017 and held it in 16 quarters. The position peaked at $243K in Q3 2018. 897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
Capital Management sold 1,460 iShares Biotechnology ETF shares in Q1 2022, an estimated $223K.
Capital Management first reported a position in iShares Biotechnology ETF in Q1 2017 and held it in 16 quarters.
Capital Management's iShares Biotechnology ETF position peaked at $243K in Q3 2018.
897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Capital Management's 13F filing for Q1 2022, filed 3 May 2022.